Knoerl Robert, Wallar Jessica, Fox Erica, Hong Fangxin, Salehi Elahe, McCleary Nadine, Ligibel Jennifer A, Reyes Kaitlen, Berry Donna L
Author Affiliations: Phyllis F. Cantor Center for Research and Nursing and Patient Care Services (Dr Knoerl, Ms Wallar, and Ms Fox), Department of Data Sciences (Dr Hong), and Medical Oncology (Drs Salehi, McCleary, Ligibel, and Reyes), Dana-Farber Cancer Institute, Boston, Massachusetts; and Biobehavioral Nursing and Health Informatics, University of Washington, Seattle (Dr Berry).
Cancer Nurs. 2023;46(2):103-110. doi: 10.1097/NCC.0000000000001082. Epub 2022 Mar 14.
Quantitative reports suggest that the assessment and management of chemotherapy-induced peripheral neuropathy (CIPN) in practice is suboptimal.
The purpose of this qualitative analysis was to explore clinician-related perspectives of CIPN assessment, management, and the use of a CIPN decision support tool.
Clinicians from the breast oncology, gastrointestinal oncology, or multiple myeloma disease centers at Dana-Farber Cancer Institute who interacted with a CIPN clinician decision support algorithm were eligible to participate in the semi-structured interviews. The interview guide included questions about CIPN assessment, management, and clinician-decision support tool use. All interviews were audio-recorded, transcribed, and analyzed using inductive content analysis.
Of the 39 eligible clinicians, 15 agreed to be interviewed. Interviewed clinicians were mainly physicians (73.3) and White, non-Hispanic (93.3%). Main themes from the interviews included (1) CIPN management practice patterns (eg, endorsement of non-recommended management strategies or lack of standardization for chemotherapy dose reduction) and barriers (eg, insurance prior authorizations required for duloxetine prescription), (2) CIPN assessment practice patterns (eg, use of subjective instead of objective CIPN assessment approaches) and barriers (eg, difficult to interpret patients' CIPN report between visits), and (3) utilization of the clinician decision support tool (eg, all assessment tasks lead to same management options).
There are several barriers to clinicians' use of evidence-based CIPN assessment and management strategies.
Future work should be focused on addressing barriers to duloxetine prescription, developing evidence-based CIPN assessment and management strategies, improving symptom monitoring, and facilitating referrals to existing supportive care services.
定量报告显示,化疗引起的周围神经病变(CIPN)在实际临床中的评估与管理并不理想。
本定性分析旨在探究临床医生对CIPN评估、管理以及使用CIPN决策支持工具的相关观点。
来自达纳-法伯癌症研究所乳腺肿瘤、胃肠道肿瘤或多发性骨髓瘤疾病中心且使用过CIPN临床医生决策支持算法的临床医生有资格参与半结构化访谈。访谈指南包含有关CIPN评估、管理以及临床医生决策支持工具使用的问题。所有访谈均进行录音、转录,并采用归纳性内容分析法进行分析。
在39名符合条件的临床医生中,15名同意接受访谈。接受访谈的临床医生主要是医生(73.3%),且为非西班牙裔白人(93.3%)。访谈的主要主题包括:(1)CIPN管理实践模式(如认可未被推荐的管理策略或化疗剂量降低缺乏标准化)及障碍(如度洛西汀处方需要保险预先授权);(2)CIPN评估实践模式(如使用主观而非客观的CIPN评估方法)及障碍(如两次就诊之间难以解读患者的CIPN报告);(3)临床医生决策支持工具的使用情况(如所有评估任务都导致相同的管理选项)。
临床医生在使用基于证据的CIPN评估和管理策略方面存在若干障碍。
未来工作应聚焦于解决度洛西汀处方的障碍、制定基于证据的CIPN评估和管理策略、改善症状监测以及促进转介至现有的支持性护理服务。